[Investor Updates] PharmAbcine, non-confidential slide deck Q3 2020
18 Sep 2020
[Investor Updates] PharmAbcine, non-confidential slide deck Q3 2020
2F, Research Building 2, 70,
Yuseong-daero 1689 beon-gil,
Yuseong-gu, Daejeon, 34047, Republic of Korea
HQ +82-42-863-2017
R&D Center +82-42-861-2017
Investor Relations +70-4294-6097
FAX +82-42-863-2080
COPYRIGHT BY PharmAbcine Inc.
ALL RIGHTS RESERVE
Category
PharmAbcine, non-confidential slide deck Q3 2020
Notice of Changes:
1) the National Institute of Allergy and Infectious Diseases(NIAID) to treat Systemic Capillary Leak Syndrome
(SCLS, Clarkson Disease)
2) Wuxi Shuangliang Biotechnology (SLBio), a Chinese biotech, to treat non-small cell lung cancer (NSCLC) have been
added. Other changes in layouts and designs have also been made.
Please check the attached file for details.